ADVFN US – Market Content Editor

Alibaba Group (NYSE:BABA) shares jumped Wednesday after the Chinese e-commerce titan unveiled plans to significantly boost spending on artificial intelligence infrastructure and revealed a new collaboration with AI powerhouse Nvidia (NASDAQ:NVDA). As of 8:44 AM ET, Alibaba ADRs traded in the U.S. were up 8.9% at $177.70, while shares listed in Hong Kong climbed 9.2%…

U.S. crude oil inventories fell last week, according to the Energy Information Administration (EIA), but the decline was smaller than analysts had forecasted. The EIA reported that commercial crude oil stocks decreased by 607,000 barrels, below the expected drop of 800,000 barrels. Compared to the steep 9.285 million-barrel decline recorded the prior week, this week’s…

Levi Strauss & Co. (NYSE:LEVI) Class A shares climbed to a 52-week high of $23.41, highlighting a strong upward trend over the past year. Over the last 12 months, the stock has gained 11.35%, signaling steady growth and growing investor confidence. The company’s market strength and strategic initiatives have contributed to this positive momentum, underscoring…

Copper prices surged roughly 2% in intraday trading Wednesday after Freeport-McMoRan (NYSE:FCX) outlined the significant production shortfall caused by the suspension of its Grasberg Block Cave mine in Indonesia following a fatal mud rush. The mining giant confirmed that operations remain halted after two workers were killed, while search efforts continue for five missing employees.…

U.S. building permits fell modestly in the latest report, registering a -2.3% change, slightly improving on economists’ dismal forecast of -3.7%. While the decline indicates some cooling in the construction sector, the numbers suggest the contraction is less severe than anticipated. Building permits, which reflect upcoming construction activity including financing, employment, and regulatory approvals, are…

uniQure N.V. (NASDAQ:QURE) stock surged 150% Wednesday following the announcement of encouraging topline results from its pivotal Phase I/II study of AMT-130 in patients with Huntington’s disease, showing substantial slowing of disease progression compared to controls. The trial successfully hit its primary endpoint, with high-dose AMT-130 demonstrating a 75% reduction in disease progression at 36…